2000
The Cytonet Group was founded as a spinoff from the cell therapy division of Roche Diagnostics GmbH.
…………………………………………………………………………………………………………………………………………………………………………
2001
Cytonet was established as Germany’s leading company in the field of cell therapy, with production sites
in Hanover and Heidelberg.
Dietmar Hopp, co-founder of SAP, invests in Cytonet. Dietmar Hopp and his family are now the majority shareholders.
…………………………………………………………………………………………………………………………………………………………………………
2004
Physicians succeed in saving the life of a female patient with a life-threatening acute liver failure using
the Cytonet liver cell therapy.
…………………………………………………………………………………………………………………………………………………………………………
2006
Cytonet was the first company in the world to receive a production permit for a medicinal product
based on human liver cells.
The European medicinal product authority EMEA recognized the Cytonet liver cell therapy as a
medicinal product for use in the treatment of rare diseases (orphan drug).
Cytonet entered the US market by way of a cooperation with the company Vesta Therapeutics Inc. Liver
cells for the Cytonet preparation were processed at the location of this US partner in Durham NC. t.
…………………………………………………………………………………………………………………………………………………………………………
2007
Cytonet received the German Business Innovation Prize.
…………………………………………………………………………………………………………………………………………………………………………
2008
First successful treatment of a newborn with congenital urea cycle defect with liver cells.
The SELICA II study begins. Within the framework of the study, a new therapeutic option was
offered to neonates with severe metabolic disorders of the liver, increasing their chances of survival.
Cytonet assumed ownership of the lease agreement of the production facilities of VESTA Therapeutics
Inc., giving the company a US headquarters and production facility of its own in North America.
…………………………………………………………………………………………………………………………………………………………………………
2010
Start of collaboration between Cytonet, the Heidelberg University Pediatric Hospital and the
Hamad-Medical-Center in Doha, Qatar
SELICA trial extended to include the USA
…………………………………………………………………………………………………………………………………………………………………………
2011
The Canadian health authority, Health Canada, recently granted Cytonet approval to extend the
SELICA III trial into Canada
…………………………………………………………………………………………………………………………………………………………………………
2012
After being granted approval by the German Federal Institute of Drugs and Medical Devices
(BfArM), a clinical trial on the diagnostics of urea cycle defects is being launched at Heidelberg
University Hospital, led by Prof. Dr. med. Prof. h.c. (RCH) Georg Friedrich Hoffmann.
On July Cytonet received approval for the import, testing and batch release of somatic cell
therapeutics for use in clinical trials according to § 72 Section 1 and § 13 Section 1 of the drug law
